On Wednesday, BIO released the largest ever study of clinical development success rates. The study, conducted in partnership with Amplion and Biomedtracker, recorded and analyzed 9,985 clinical and regulatory phase transitions, across 1,103 companies. Using clinical trial data from the past decade,…

Writing in the Wall Street Journal today, Eli Lilly and Company Chairman, President and CEO John Lechleiter examines proposals that would require pharmaceutical companies to disclose detailed information about the cost of R&D for individual drugs and the extent of discounts offered to insurers…

The 2016 BIO CEO & Investor Conference isn’t just for biotech companies and the investment community, the conference featured a strong patient voice and focus on the patient perspective in drug development and drug delivery. Two of the most highly-attended panel discussions were moderated by…

Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, researchers and investors working in this field have firmly established themselves at the forefront of medical innovation and the search for new cures and therapies for previously untreatable diseases…

Working alongside scientists, universities, and biotech companies, patients and patient organizations have the ability to play a critical role in the search for treatments and cures for chronic and deadly diseases.  As part of the 5th authorization of the Prescription Drug User Fee Act (PDUFA V),…

Last week, Rep. Fred Upton (R-MI) published an op-ed – How to Breathe New Life Into America’s Health-Care System – in Time Magazine on the potential of the 21st Century Cures Act to ‘help modernize the health-care innovation infrastructure, incorporate a patient perspective into the drug and device…

Drug development is expensive.  Drug development is risky.  Drug development takes a long time. The key to changing this is leveraging the fact that no one is more motivated to eliminate rare disease than those who are directly affected by it. I know this because, as the founder of Give RARE, I…

A new report from the National Bureau of Economic Research (NBER) has determined that strong patent protection accelerates the speed at which new drugs are launched in different countries. Providing affordable access is often challenged by the need to provide adequate incentives for developing new…

In the October issue of MedNous, Alkermes' CEO Richard Pops writes about the move toward increased engagement with patients in the development, review and delivery of new medicines, as well as the challenges and opportunities associated with access and reimbursement. Pops asserts that patients must…

An editorial in today's Wall Street Journal looks at the rising threat the American insurance industry’s increasingly loud attacks on Sovaldi, a revolutionary new Hepatitis C treatment pose for medical innovation and the development of new specialty drugs. As the editors rightly note, “Sovaldi is…